# Simeon George

> Simeon George is a Series B investor at SR One (San Francisco) backing Biotechnology and Medical. See 24 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [SR One](https://shizune.co/investors/profile/sr-one)
- Location: San Francisco, United States
- Total investments: 24
- Last investment: Jul 2026
- Lead investor: 46%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/simeon-george-b2707985/

Simeon George is a Series B investor at SR One in San Francisco focused on Biotechnology and Medical. Simeon joined SR One in 2007 and leads SR Ones investment activities on the West Coast. Prior to joining SR One, Simeon was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch.Simeon received his BA in Neuroscience from the Johns Hopkins University, where he graduated Phi Betta Kappa. Simeon receivedhis MD from the University of Pennsylvania School of Medicine and his MBA (Mayer Scholar) from the Wharton School of the University of Pennsylvania.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 13 | 54% |
| Medical | 7 | 29% |
| Life Science | 6 | 25% |
| Health Care | 5 | 21% |
| Therapeutics | 4 | 17% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 9 | 38% |
| Series A | 6 | 25% |
| Series C | 2 | 8% |
| Series D | 2 | 8% |
| Private Equity | 1 | 4% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 13 | 54% |
| Israel | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Fore Biotherapeutics | We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M | Series D | Jul 07, 2026 |  |
| Fore Biotherapeutics | We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $40.2M | Series D | May 06, 2025 |  |
| ADARx Pharmaceuticals | ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired andfunctional protein is restored. It was founded in 2019 and is headquartered in San Diego, California. | $200M | Series C | Aug 09, 2023 |  |
| ADARx Pharmaceuticals | ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired andfunctional protein is restored. It was founded in 2019 and is headquartered in San Diego, California. | $46M | Series B | Jan 20, 2023 |  |
| Rezo Therapeutics | Rezo Therapeutics identifies targets and therapies by combining distinct, unbiased technologies with artificial intelligence. Rezo's proprietary platform can be used to treat a wide range of diseases. Rezo's initial focus is oncology, with plans to expand into other therapeutic areas through collaborations and partnerships. | $78M | Series A | Nov 17, 2022 |  |
| Simcha Therapeutics | Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer. The company uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system. Simcha’s lead program, ST-067, is a designer IL-18 cytokine that has shown potent antitumor effects in animalmodels, both as a monotherapy and when combined with anti-PD-1 checkpoint inhibitors, as described in Nature in June 2020.It was founded in 2018 and is headquartered in New Haven, Connecticut, USA. | $40M | Series B | Jan 27, 2022 |  |
| ADARx Pharmaceuticals | ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired andfunctional protein is restored. It was founded in 2019 and is headquartered in San Diego, California. | $75M | Series B | Sep 08, 2021 |  |
| Design Therapeutics | Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company’s lead program is focused on the treatment of Friedreich’s ataxia and discovery efforts are ongoing in other degenerative diseases. | $125M | Series B | Jan 27, 2021 |  |
| Design Therapeutics | Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company’s lead program is focused on the treatment of Friedreich’s ataxia and discovery efforts are ongoing in other degenerative diseases. | $45.5M | Series A | Mar 20, 2020 |  |
| Turning Point Therapeutics | Turning Point Therapeutics is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. They focus on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potentialtargets regulating the tumor microenvironment and tumor immunity. | $80M | Private Equity | Oct 19, 2018 |  |

10 of 24 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 9 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 5 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 4 deals together
- [M Ventures](https://shizune.co/investors/profile/merckventures) — VC Fund, 4 deals together
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 4 deals together
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 3 deals together

## About SR One

VC Fund · Cambridge, United States

SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.

5 contacts available at SR One.

| Name | Title | Profile |
| --- | --- | --- |
| Jill Carroll | Partner | https://shizune.co/investors/profile/jill-carroll |
| Simeon George | Chief Executive Officer | https://shizune.co/investors/profile/simeon-j-george |
| Christopher Y. Chai | Venture Partner | https://shizune.co/investors/profile/christopher-y-chai |
| Iqbal Mufti | Partner | https://shizune.co/investors/profile/iqbal-mufti-e58a |
| Jens Eckstein | President | https://shizune.co/investors/profile/jens-eckstein |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Simeon George invest in?

Simeon George invests primarily in Biotechnology, Medical and Life Science startups, most often at Series B and Series A stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Simeon George last invest?

The most recent investment recorded for Simeon George closed in Jul 2026. Shizune tracks 24 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co